Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of Extended Release Tacrolimus (Advagraf®) + Sirolimus (Rapamune®), Versus Extended Release Tacrolimus (Advagraf®) + Mycophenolate Mofetil in Kidney Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients aged over 20 years~* Patient who is judged would have the benefits of the Extended Release Tacrolimus (Advagraf®)treatment by the investigator~* Patients has given written informed consent~* Patient is a recipient of primary or recipient of primary (a living kidney transplant, a cadaveric donor.)~* Patients has received an ABO compatible donor kidney.~* Complement-dependent Cytotoxic Crossmatch: CDC) result: negative~* Female patients of child bearing potential must have a negative urine or serum pregnancy test within 7 days prior to enrollment or upon hospitalization~Exclusion Criteria:~* Patient has previously received an organ transplant other than a kidney.~* Patient has a known hypersensitivity to tacrolimus, Sirolimus (Rapamune®),Mycophenolate mofetil.~* Desensitization~* HLA-identical~* Heart Disease; Heart failure (symptom, EF \<45%)~* Lung Disease; Significant chronic obstructive pulmonary disease, restrictive lung disease~* Patient has an uncontrolled concomitant infection (including Hepatitis B, Hepatitis C) or any other unstable~* malignant tumor history in the 5years prior to enrollment. (except,squamous cell carcinoma)~* Patient has received a kidney transplant from non-heart beating donor~* Cold ischemic time \> 30hrs~* Elevated AST and/or ALT levels greater than 3 times the upper value of the normal range of the investigational site~* (ANC)\<1,500/mm3, (WBC)\<2,500/ mm3, (PLT)\<100,000/ mm3~* ATG: Anti-thymocyte globulin induction~* Medical condition that could interfere with the study objectives.~* Patient is currently taking or has been taking an investigational products in the 30 days prior to enrollment.~* Patient is currently taking or has been taking an prohibited medications in the 28 days prior to enrollment.~* Patient who is judged not to be adequate by the investigator owing to other reasons~* Patient is pregnant or lactating.~* Recipient or donor is known to be seropositive for human immunodeficiency virus.(HIV)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A) TEST (Type: ACTIVE_COMPARATOR): None
- B) CONTROL (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).